Breaking News
Get 50% Off 0
🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% Off CLAIM SALE
Close

TheraCryf PLC (TCF)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.80 0.00    0.00%
12/07 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 1,005
  • Bid/Ask: 0.65 / 0.85
  • Day's Range: 0.80 - 0.85
Type:  Equity
Market:  United Kingdom
ISIN:  GB00BSVYN304 
SEDOL:  BSVYN30
TheraCryf 0.80 0.00 0.00%

TheraCryf Company Profile

 
Read the TheraCryf PLC company profile to learn more about the business and the management team. View TheraCryf PLC facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

10

Equity Type

ORD

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company’s lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Contact Information

Address Alderley Park Suite 24G13 - Block 24
Congleton Road Nether Alderley, SK10 4TG
United Kingdom
Phone 44 1625 315 090
Fax -

Top Executives

Name Age Since Title
Huw Jones 65 2020 CEO & Executive Director
Alan John Barge 67 2015 Independent Non-Executive Director
Toni Haenninen 47 2023 CFO & Director
Susan Elizabeth Foden 71 2014 Chair & Senior Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TCF Price Commentary

Write your thoughts about TheraCryf PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Paul Timmins
Paul Timmins Oct 23, 2020 8:21
Saved. See Saved Items.
This comment has already been saved in your Saved Items
just won 2 million bullish
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email